Skip to NavigationSkip to content


Gilead and Galapagos' ankylosing spondylitis drug hits Phase 2 trial goal

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase 2 trial investigating its efficacy in the treatment of moderately to severely active ankylosing spondylitis (AS) in adult patients.

Specifically, the therapy was found to lead to “significantly greater improvements” in AS Disease Activity Score (ASDAS) – the trial’s primary endpoint – after 12 weeks of treatment; the mean change of -1.5 versus -0.6 for placebo, while 76% of patients taking filgotinib achieved an ASAS response of 20 compared to

Gilead steps in to rescue Galapagos RA drug

Gilead sign

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory diseases under development by Galapagos Pharma.

The deal means Gilead will pay Galapagos an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches